BR112018000297A2 - polimorfo de macrociclo de diarila - Google Patents

polimorfo de macrociclo de diarila

Info

Publication number
BR112018000297A2
BR112018000297A2 BR112018000297A BR112018000297A BR112018000297A2 BR 112018000297 A2 BR112018000297 A2 BR 112018000297A2 BR 112018000297 A BR112018000297 A BR 112018000297A BR 112018000297 A BR112018000297 A BR 112018000297A BR 112018000297 A2 BR112018000297 A2 BR 112018000297A2
Authority
BR
Brazil
Prior art keywords
polymorph
macrocycle
diaryl
diaryl macrocycle
macrocycle polymorph
Prior art date
Application number
BR112018000297A
Other languages
English (en)
Inventor
W Rogers Evan
J Cui Jingrong
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of BR112018000297A2 publication Critical patent/BR112018000297A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR112018000297A 2015-07-06 2016-07-05 polimorfo de macrociclo de diarila BR112018000297A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US201562218672P 2015-09-15 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (1)

Publication Number Publication Date
BR112018000297A2 true BR112018000297A2 (pt) 2018-09-04

Family

ID=57685592

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000297A BR112018000297A2 (pt) 2015-07-06 2016-07-05 polimorfo de macrociclo de diarila

Country Status (14)

Country Link
US (4) US10294242B2 (pt)
EP (1) EP3319969B1 (pt)
JP (2) JP6917974B2 (pt)
KR (1) KR102623734B1 (pt)
CN (2) CN108026108B (pt)
AU (1) AU2016289454B2 (pt)
BR (1) BR112018000297A2 (pt)
CA (1) CA2990020C (pt)
HK (1) HK1254492A1 (pt)
IL (2) IL256443B (pt)
MX (2) MX2017017081A (pt)
RU (1) RU2765181C2 (pt)
WO (1) WO2017007759A1 (pt)
ZA (1) ZA201708436B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735729T3 (es) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018001065A2 (pt) * 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos
MX2019001125A (es) 2016-07-28 2019-06-12 Tp Therapeutics Inc Inhibidores de cinasa macrociclica.
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技(苏州)有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
CN113956269A (zh) * 2018-04-16 2022-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
CN113490664A (zh) 2018-10-22 2021-10-08 埃斯克疗法股份有限公司 Tyk2抑制剂和其用途
EP3974434A4 (en) 2019-05-21 2023-11-08 Zhejiang Hisun Pharmaceutical Co., Ltd. MACROLIDE DERIVATIVES, PRODUCTION PROCESS AND USE THEREOF
CA3143043A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
CA3163095A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
CN114901286B (zh) * 2019-11-27 2024-05-10 特普医药公司 涉及二芳基巨环化合物的组合疗法
KR20230022151A (ko) * 2020-03-02 2023-02-14 터닝 포인트 테라퓨틱스, 인크. 거대고리 화합물의 치료 용도
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9403639D0 (en) * 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
WO2003011222A2 (en) * 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
MX2011002470A (es) 2008-09-08 2011-04-05 Merck Patent Gmbh Pirimidinas macrociclicas como inhibidores de aurora cinasa.
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
KR101634833B1 (ko) 2008-10-22 2016-06-29 어레이 바이오파마 인크. TRK 키나아제 억제제로서 치환된 피라졸로[1,5­a] 피리미딘 화합물
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
AU2012299223A1 (en) * 2011-08-19 2014-02-27 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
JP6046728B2 (ja) 2011-09-30 2016-12-21 オンコデザイン エス.ア. 大環状flt3キナーゼ阻害剤
CN104169286B (zh) 2012-03-06 2016-06-08 辉瑞大药厂 用于治疗增殖性疾病的大环衍生物
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10497029B2 (en) * 2013-10-21 2019-12-03 Disney Enterprises, Inc. Systems and methods for facilitating brand integration within online content and promoting that online content
ES2735729T3 (es) * 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
US10316044B2 (en) * 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018001065A2 (pt) * 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos

Also Published As

Publication number Publication date
JP2018529633A (ja) 2018-10-11
HK1254492A1 (zh) 2019-07-19
EP3319969B1 (en) 2024-04-03
MX2021008145A (es) 2021-08-11
ZA201708436B (en) 2021-03-31
EP3319969A4 (en) 2019-07-03
IL283184A (en) 2021-06-30
JP2021119151A (ja) 2021-08-12
IL256443B (en) 2021-05-31
JP7212713B2 (ja) 2023-01-25
AU2016289454B2 (en) 2020-07-09
WO2017007759A1 (en) 2017-01-12
CA2990020C (en) 2024-02-27
EP3319969A1 (en) 2018-05-16
IL256443A (en) 2018-02-28
RU2018104269A3 (pt) 2019-12-17
CN108026108A (zh) 2018-05-11
US10294242B2 (en) 2019-05-21
RU2765181C2 (ru) 2022-01-26
CN113354653A (zh) 2021-09-07
JP6917974B2 (ja) 2021-08-11
KR20180026480A (ko) 2018-03-12
MX2017017081A (es) 2018-08-16
CN108026108B (zh) 2021-06-22
RU2018104269A (ru) 2019-08-06
IL283184B2 (en) 2023-06-01
US20190233437A1 (en) 2019-08-01
US20230295184A1 (en) 2023-09-21
AU2016289454A1 (en) 2018-01-04
US20210094974A1 (en) 2021-04-01
US20180194777A1 (en) 2018-07-12
CA2990020A1 (en) 2017-01-12
KR102623734B1 (ko) 2024-01-10

Similar Documents

Publication Publication Date Title
BR112018000297A2 (pt) polimorfo de macrociclo de diarila
DK3283625T3 (da) Nukleasemedieret genomeditering
CL2016002129A1 (es) Compuestos de azolina
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
MA54568A (fr) Substitutions de nucléotides prédéterminées
DK3331529T3 (da) Muskarinagonister
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3270930T3 (da) Præeklampsi
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3394281T3 (da) Gærcelle
DK3286260T3 (da) Polyolefinrør
DK3292136T3 (da) Penicillin-g-acylaser
DK3597189T3 (da) Krystallinske forbindelser
DE112015006486A5 (de) Inkubationsrinne
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
DK3318308T3 (da) Badmintonketsjer
DK3274482T3 (da) Stenborsknop
ES1141731Y (es) Cepillo de Dientes
ES2789757T8 (es) Herramienta de conformado
DE112016005599A5 (de) Strahlungsgrill

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TURNING POINT THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]